1310 related articles for article (PubMed ID: 17904457)
1. Obesity paradox in patients with hypertension and coronary artery disease.
Uretsky S; Messerli FH; Bangalore S; Champion A; Cooper-Dehoff RM; Zhou Q; Pepine CJ
Am J Med; 2007 Oct; 120(10):863-70. PubMed ID: 17904457
[TBL] [Abstract][Full Text] [Related]
2. The relationship of body mass index to outcomes after percutaneous coronary intervention.
Shubair MM; Prabhakaran P; Pavlova V; Velianou JL; Sharma AM; Natarajan MK
J Interv Cardiol; 2006 Oct; 19(5):388-95. PubMed ID: 17020562
[TBL] [Abstract][Full Text] [Related]
3. Relation of body mass index to outcome in patients with known or suspected coronary artery disease.
Galal W; van Domburg RT; Feringa HH; Schouten O; Elhendy A; Bax JJ; Awara AM; Klein J; Poldermans D
Am J Cardiol; 2007 Jun; 99(11):1485-90. PubMed ID: 17531566
[TBL] [Abstract][Full Text] [Related]
4. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
[TBL] [Abstract][Full Text] [Related]
5. Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Pepine CJ; Kowey PR; Kupfer S; Kolloch RE; Benetos A; Mancia G; Coca A; Cooper-DeHoff RM; Handberg E; Gaxiola E; Sleight P; Conti CR; Hewkin AC; Tavazzi L;
J Am Coll Cardiol; 2006 Feb; 47(3):547-51. PubMed ID: 16458134
[TBL] [Abstract][Full Text] [Related]
6. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative.
Diercks DB; Roe MT; Mulgund J; Pollack CV; Kirk JD; Gibler WB; Ohman EM; Smith SC; Boden WE; Peterson ED
Am Heart J; 2006 Jul; 152(1):140-8. PubMed ID: 16824844
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Cooper-DeHoff RM; Aranda JM; Gaxiola E; Cangiano JL; Garcia-Barreto D; Conti CR; Hewkin A; Pepine CJ;
Am Heart J; 2006 May; 151(5):1072-9. PubMed ID: 16644338
[TBL] [Abstract][Full Text] [Related]
8. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox.
Badheka AO; Rathod A; Kizilbash MA; Garg N; Mohamad T; Afonso L; Jacob S
Am J Med; 2010 Jul; 123(7):646-51. PubMed ID: 20609687
[TBL] [Abstract][Full Text] [Related]
9. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
10. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
Ried LD; Tueth MJ; Handberg E; Kupfer S; Pepine CJ;
Psychosom Med; 2005; 67(3):398-406. PubMed ID: 15911902
[TBL] [Abstract][Full Text] [Related]
11. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Cooper-Dehoff R; Cohen JD; Bakris GL; Messerli FH; Erdine S; Hewkin AC; Kupfer S; Pepine CJ;
Am J Cardiol; 2006 Oct; 98(7):890-4. PubMed ID: 16996868
[TBL] [Abstract][Full Text] [Related]
12. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
de Simone G; Wachtell K; Palmieri V; Hille DA; Beevers G; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Devereux RB
Circulation; 2005 Apr; 111(15):1924-31. PubMed ID: 15837945
[TBL] [Abstract][Full Text] [Related]
13. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
14. [Impact of overweight on clinical outcomes in patients undergoing coronary revascularization].
Kang JP; Ma CS; Lü Q; Nie SP; Liu XM; Liu XH; DU X; Hu R; Dong JZ; Chen F; Lü SZ; Gu CX; Huang FJ; Wu XS
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1381-4. PubMed ID: 20646625
[TBL] [Abstract][Full Text] [Related]
15. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery.
Mullen JT; Moorman DW; Davenport DL
Ann Surg; 2009 Jul; 250(1):166-72. PubMed ID: 19561456
[TBL] [Abstract][Full Text] [Related]
16. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.
Sarno G; Räber L; Onuma Y; Garg S; Brugaletta S; van Domburg RT; Pilgrim T; Pfäffli N; Wenaweser P; Windecker S; Serruys P
Am J Cardiol; 2011 Jul; 108(2):195-201. PubMed ID: 21529741
[TBL] [Abstract][Full Text] [Related]
17. Impact of neurohormonal blockade on association between body mass index and mortality.
Kennedy LM; Anker SD; Kjekshus J; Cook TJ; Willenheimer R
Int J Cardiol; 2007 Jun; 119(1):33-40. PubMed ID: 17052777
[TBL] [Abstract][Full Text] [Related]
18. Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher long-term risks including recurrent re-infarction and cardiac death.
Nigam A; Wright RS; Allison TG; Williams BA; Kopecky SL; Reeder GS; Murphy JG; Jaffe AS
Int J Cardiol; 2006 Jun; 110(2):153-9. PubMed ID: 16043245
[TBL] [Abstract][Full Text] [Related]
19. Obesity and the risk of death after acute myocardial infarction.
Rana JS; Mukamal KJ; Morgan JP; Muller JE; Mittleman MA
Am Heart J; 2004 May; 147(5):841-6. PubMed ID: 15131540
[TBL] [Abstract][Full Text] [Related]
20. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
Othman M; Kawar B; El Nahas AM
Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
